Publication: Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
dc.contributor.author | Molina-Ortega, A | |
dc.contributor.author | Martin-Gandul, C | |
dc.contributor.author | Mena-Romo, J D | |
dc.contributor.author | Rodriguez-Hernandez, M J | |
dc.contributor.author | Suñer, M | |
dc.contributor.author | Bernal, C | |
dc.contributor.author | Sanchez, M | |
dc.contributor.author | Sanchez-Cespedes, J | |
dc.contributor.author | Perez Romero, P | |
dc.contributor.author | Cordero, E | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases | |
dc.date.accessioned | 2023-01-25T10:22:54Z | |
dc.date.available | 2023-01-25T10:22:54Z | |
dc.date.issued | 2018-10-05 | |
dc.description.abstract | Although solid organ transplant (SOT) recipients with pretransplant serology for cytomegalovirus (CMV-R+) are considered at intermediate risk for CMV infection post transplantation, CMV infection remains a major cause of morbidity in this population. We prospectively characterized whether having pretransplant CMV-specific cellular immunity is independently associated with controlling infection after transplantation in R + SOT recipients. A prospective cohort of consecutive R + SOT recipients that received pre-emptive treatment for CMV infection was monitored after transplantation and variables were recorded during the follow-up. The cytomegalovirus-specific T-cell immune response was characterized by intracellular cytokine staining and viral loads determined using real-time PCR. One hundred and thirty-five R + SOT recipients were included (67 kidney, 64 liver, four liver-kidney). Only one-third of the patients (42; 31.85%) had CMV-specific T-cell immunity (CD8+CD69+INF-γ+ T cells >0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p 0.25%) before transplantation. Patients with negative pretransplant immunity had more CMV infection (49, 52.7% vs. 15, 35.7%; p 0.07) and received more antiviral therapy than those with immunity (32, 34.4% vs. 6, 14.3%, p 0.016). Having CMV specific immunity was an independent factor for protection from developing viraemia ≥2000 IU/mL (OR 0.276, 95% CI 0.105-0.725, p Our results show that having a pretransplant CMV specific T-cell response may be associated with a lower rate of CMV viraemia and less antiviral treatment after transplantation; however, more prospective studies are needed to confirm these findings. | |
dc.description.version | Si | |
dc.identifier.citation | Molina-Ortega A, Martín-Gandul C, Mena-Romo JD, Rodríguez-Hernández MJ, Suñer M, Bernal C, et al. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect. 2019 Jun;25(6):753-758. | |
dc.identifier.doi | 10.1016/j.cmi.2018.09.019 | |
dc.identifier.essn | 1469-0691 | |
dc.identifier.pmid | 30292792 | |
dc.identifier.unpaywallURL | http://www.clinicalmicrobiologyandinfection.com/article/S1198743X18306578/pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/13037 | |
dc.issue.number | 6 | |
dc.journal.title | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | |
dc.journal.titleabbreviation | Clin Microbiol Infect | |
dc.language.iso | en | |
dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | 753-758 | |
dc.provenance | Realizada la curación de contenido 18/02/2025 | |
dc.publisher | Elsevier Ltd | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Observational Study | |
dc.relation.projectID | PI11-02800 | |
dc.relation.projectID | PI11-01357 | |
dc.relation.projectID | PI14-00165 | |
dc.relation.projectID | REIPI RD12/0015/0001 | |
dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S1198-743X(18)30657-8 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | CMV | |
dc.subject | CMV-specific immune response | |
dc.subject | Cytomegalovirus infection | |
dc.subject | Replication episodes | |
dc.subject | Serological status | |
dc.subject | Solid organ transplantation | |
dc.subject.decs | Inmunidad | |
dc.subject.decs | Infecciones | |
dc.subject.decs | Trasplante | |
dc.subject.decs | Terapéutica | |
dc.subject.decs | Linfocitos T | |
dc.subject.decs | Antivirales | |
dc.subject.decs | Pacientes | |
dc.subject.decs | Citomegalovirus | |
dc.subject.decs | Hígado | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Cytokines | |
dc.subject.mesh | Cytomegalovirus | |
dc.subject.mesh | Cytomegalovirus Infections | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Organ Transplantation | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Staining and Labeling | |
dc.subject.mesh | T-Lymphocytes | |
dc.subject.mesh | Viral Load | |
dc.subject.mesh | Young Adult | |
dc.title | Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 25 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format